Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company VetbiolixRamat Gan, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Can-Fite ...

Real-world data is increasingly used to optimize trial design, reduce recruitment burden, and support regulatory decisions, but adoption remains uneven due to challenges around data quality, ...

Overcoming common challenges with today’s biologics, such as developing devices for high-concentration subcutaneous ...

Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near-maximal responses achieved in ~90% of patients – – Rademikibart ...

Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated ...

April 01, 2026 - PRESSADVANTAGE - As global collaboration across healthcare, biotechnology, and medical research ...

When patient safety, regulatory approval and real-world effectiveness are on the line, AI can't act autonomously.

Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV 1 with many ...

The European Medicines Agency has finalized its reflection paper on a tailored clinical approach to biosimilar development, ...

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading ...

A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes ...

How a Verified Research Peptide Supplier Is Changing Lab Procurement Standards California, United States - April 1, ...